196 related articles for article (PubMed ID: 33075177)
21. Prostate Cancer Differentiation and Aggressiveness: Assessment With a Radiomic-Based Model vs. PI-RADS v2.
Chen T; Li M; Gu Y; Zhang Y; Yang S; Wei C; Wu J; Li X; Zhao W; Shen J
J Magn Reson Imaging; 2019 Mar; 49(3):875-884. PubMed ID: 30230108
[TBL] [Abstract][Full Text] [Related]
22. Prospective comparison of a fast 1.5-T biparametric with the 3.0-T multiparametric ESUR magnetic resonance imaging protocol as a triage test for men at risk of prostate cancer.
Van Nieuwenhove S; Saussez TP; Thiry S; Trefois P; Annet L; Michoux N; Lecouvet F; Tombal B
BJU Int; 2019 Mar; 123(3):411-420. PubMed ID: 30240059
[TBL] [Abstract][Full Text] [Related]
23. Biparametric 3T Magnetic Resonance Imaging for prostatic cancer detection in a biopsy-naïve patient population: a further improvement of PI-RADS v2?
Stanzione A; Imbriaco M; Cocozza S; Fusco F; Rusconi G; Nappi C; Mirone V; Mangiapia F; Brunetti A; Ragozzino A; Longo N
Eur J Radiol; 2016 Dec; 85(12):2269-2274. PubMed ID: 27842676
[TBL] [Abstract][Full Text] [Related]
24. Direct Comparison of PI-RADS Version 2 and 2.1 in Transition Zone Lesions for Detection of Prostate Cancer: Preliminary Experience.
Byun J; Park KJ; Kim MH; Kim JK
J Magn Reson Imaging; 2020 Aug; 52(2):577-586. PubMed ID: 32045072
[TBL] [Abstract][Full Text] [Related]
25. Visibility of significant prostate cancer on multiparametric magnetic resonance imaging (MRI)-do we still need contrast media?
Huebner NA; Korn S; Resch I; Grubmüller B; Gross T; Gale R; Kramer G; Poetsch N; Clauser P; Haitel A; Fajkovic H; Shariat SF; Baltzer PA
Eur Radiol; 2021 Jun; 31(6):3754-3764. PubMed ID: 33263793
[TBL] [Abstract][Full Text] [Related]
26. Added value of diffusion-weighted images and dynamic contrast enhancement in multiparametric magnetic resonance imaging for the detection of clinically significant prostate cancer in the PICTURE trial.
Eldred-Evans D; Neves JB; Simmons LAM; Kanthabalan A; McCartan N; Shah TT; Arya M; Charman SC; Freeman A; Moore CM; Punwani S; Emberton M; Ahmed HU
BJU Int; 2020 Mar; 125(3):391-398. PubMed ID: 31733173
[TBL] [Abstract][Full Text] [Related]
27. Comparison of PI-RADS v1 and v2 for multiparametric MRI detection of prostate cancer with whole-mount histological workup as reference standard.
Schaudinn A; Gawlitza J; Mucha S; Linder N; Franz T; Horn LC; Kahn T; Busse H
Eur J Radiol; 2019 Jul; 116():180-185. PubMed ID: 31153562
[TBL] [Abstract][Full Text] [Related]
28. [Preliminary applicability evaluation of Prostate Imaging Reporting and Data System version 2 diagnostic score in 3.0T multi-parameters magnetic resonance imaging combined with prostate specific antigen density for prostate cancer].
Zuo MZ; Zhao WL; Wei CG; Zhang CY; Wen R; Gu YF; Li MJ; Zhang YY; Wu JF; Li X; Shen JK
Zhonghua Yi Xue Za Zhi; 2017 Dec; 97(47):3693-3698. PubMed ID: 29325321
[No Abstract] [Full Text] [Related]
29. Assessment of DCE Utility for PCa Diagnosis Using PI-RADS v2.1: Effects on Diagnostic Accuracy and Reproducibility.
Brancato V; Di Costanzo G; Basso L; Tramontano L; Puglia M; Ragozzino A; Cavaliere AC
Diagnostics (Basel); 2020 Mar; 10(3):. PubMed ID: 32192081
[TBL] [Abstract][Full Text] [Related]
30. An integrated nomogram combining deep learning, Prostate Imaging-Reporting and Data System (PI-RADS) scoring, and clinical variables for identification of clinically significant prostate cancer on biparametric MRI: a retrospective multicentre study.
Hiremath A; Shiradkar R; Fu P; Mahran A; Rastinehad AR; Tewari A; Tirumani SH; Purysko A; Ponsky L; Madabhushi A
Lancet Digit Health; 2021 Jul; 3(7):e445-e454. PubMed ID: 34167765
[TBL] [Abstract][Full Text] [Related]
31. Performance of Artificial Intelligence-Aided Diagnosis System for Clinically Significant Prostate Cancer with MRI: A Diagnostic Comparison Study.
Jiang KW; Song Y; Hou Y; Zhi R; Zhang J; Bao ML; Li H; Yan X; Xi W; Zhang CX; Yao YF; Yang G; Zhang YD
J Magn Reson Imaging; 2023 May; 57(5):1352-1364. PubMed ID: 36222324
[TBL] [Abstract][Full Text] [Related]
32. Comparison of biparametric MRI to full multiparametric MRI for detection of clinically significant prostate cancer.
Sherrer RL; Glaser ZA; Gordetsky JB; Nix JW; Porter KK; Rais-Bahrami S
Prostate Cancer Prostatic Dis; 2019 May; 22(2):331-336. PubMed ID: 30413806
[TBL] [Abstract][Full Text] [Related]
33. A Multireader Exploratory Evaluation of Individual Pulse Sequence Cancer Detection on Prostate Multiparametric Magnetic Resonance Imaging (MRI).
Gaur S; Harmon S; Gupta RT; Margolis DJ; Lay N; Mehralivand S; Merino MJ; Wood BJ; Pinto PA; Shih JH; Choyke PL; Turkbey B
Acad Radiol; 2019 Jan; 26(1):5-14. PubMed ID: 29705281
[TBL] [Abstract][Full Text] [Related]
34. Abbreviated Biparametric Prostate MR Imaging in Men with Elevated Prostate-specific Antigen.
Kuhl CK; Bruhn R; Krämer N; Nebelung S; Heidenreich A; Schrading S
Radiology; 2017 Nov; 285(2):493-505. PubMed ID: 28727544
[TBL] [Abstract][Full Text] [Related]
35. Comparison of multiparametric and biparametric MRI of the prostate: are gadolinium-based contrast agents needed for routine examinations?
Junker D; Steinkohl F; Fritz V; Bektic J; Tokas T; Aigner F; Herrmann TRW; Rieger M; Nagele U
World J Urol; 2019 Apr; 37(4):691-699. PubMed ID: 30078170
[TBL] [Abstract][Full Text] [Related]
36. Using support vector machine analysis to assess PartinMR: A new prediction model for organ-confined prostate cancer.
Wang J; Wu CJ; Bao ML; Zhang J; Shi HB; Zhang YD
J Magn Reson Imaging; 2018 Aug; 48(2):499-506. PubMed ID: 29437268
[TBL] [Abstract][Full Text] [Related]
37. Deep-Learning-Based Artificial Intelligence for PI-RADS Classification to Assist Multiparametric Prostate MRI Interpretation: A Development Study.
Sanford T; Harmon SA; Turkbey EB; Kesani D; Tuncer S; Madariaga M; Yang C; Sackett J; Mehralivand S; Yan P; Xu S; Wood BJ; Merino MJ; Pinto PA; Choyke PL; Turkbey B
J Magn Reson Imaging; 2020 Nov; 52(5):1499-1507. PubMed ID: 32478955
[TBL] [Abstract][Full Text] [Related]
38. Comparison of Prostate Imaging Reporting and Data System versions 1 and 2 for the Detection of Peripheral Zone Gleason Score 3 + 4 = 7 Cancers.
Krishna S; McInnes M; Lim C; Lim R; Hakim SW; Flood TA; Schieda N
AJR Am J Roentgenol; 2017 Dec; 209(6):W365-W373. PubMed ID: 28981356
[TBL] [Abstract][Full Text] [Related]
39. Usefulness of diffusion-weighted imaging and dynamic contrast-enhanced magnetic resonance imaging in the diagnosis of prostate transition-zone cancer.
Yoshizako T; Wada A; Hayashi T; Uchida K; Sumura M; Uchida N; Kitagaki H; Igawa M
Acta Radiol; 2008 Dec; 49(10):1207-13. PubMed ID: 19031184
[TBL] [Abstract][Full Text] [Related]
40. Population net benefit of prostate MRI with high spatiotemporal resolution contrast-enhanced imaging: A decision curve analysis.
Prabhu V; Rosenkrantz AB; Otazo R; Sodickson DK; Kang SK
J Magn Reson Imaging; 2019 May; 49(5):1400-1408. PubMed ID: 30629317
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
